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Clopidogrel and CYP2C19: Pharmacogenetic Testing
Ready for Clinical Prime Time?
Moderators: Michael J. Knauer1 and Eleftherios P. Diamandis2*
Experts: Jean-Sebastien Hulot,3 Richard B. Kim,4 and Derek Y.F. So5

CYP2C19 pharmacogenetic testing is currently available to
guide antiplatelet therapy; however, there are challenges
with implementing pharmacogenetic-guided therapy in
clinical practice. In this Q&A, 3 experts discuss the current
state, challenges, and future direction of CYP2C19 pharmacogenetic testing for clopidogrel therapy.
Can you briefly summarize the latest developments
and evidence for pharmacogenetic testing in patients
on clopidogrel therapy?
Jean Hulot: Clopidogrel is a prodrug that requires hepatic bioactivation to generate an active metabolite with
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antiplatelet
properties.
The CYP2C19 enzyme is
directly involved in this
bioactivation process but
its activity is genetically
determined. A common
loss-of-function genetic variant (named CYP2C19*2;
c.681G⬎A; rs4244285) is
associated with reduced formation of the clopidogrel active metabolite and reduced
pharmacodynamic response to the drug, thus resulting in high
on-treatment platelet reactivity and more frequent adverse cardiovascular events. This effect is particularly observed in homozygous carriers of the mutated allele (so-called poor metabolizers), who represent 3%–4% of Caucasian patients. The
FDA-approved drug label warns that CYP2C19 poor metabolizers may have diminished effect of the drug and suggests genetic testing to identify these patients. Finally, clopidogrel remains the most frequently prescribed P2Y12 antagonist.
Richard Kim: The clinical relevance of pharmacogenetic testing, particularly with regard to
CYP2C19 and clopidogrel, has been well documented and continues to
suggest clinical merit and
relevance.
Specifically,
there is little doubt with
regard to the importance
of CYP2C19 in the 2-step
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Dual antiplatelet therapy with clopidogrel and aspirin
has become the mainstay of therapy for patients with
acute coronary syndrome (ACS)6 undergoing percutaneous coronary interventions (PCI). Many pharmacokinetic and pharmacodynamic studies have demonstrated
substantial interindividual variation in antiplatelet response with clopidogrel, a significant proportion of
which is explained by the variation in plasma concentrations of the clopidogrel active metabolite. Clopidogrel is
a prodrug that requires bioactivation by the highly polymorphic enzyme CYP2C19 to form the active metabolite. The growing body of literature has implicated the
loss-of-function cytochrome P450, family 2, subfamily
C, polypeptide 19 variant (CYP2C19*2)7 variant with an
increased risk of major cardiovascular events. This evidence prompted the US Food and Drug Administration
(FDA) to implement a boxed warning on the clopidogrel
label describing the relationship between CYP2C19
pharmacogenetics and drug response, emphasizing the
diminished effectiveness in CYP2C19 poor metabolizers.

Q&A
bioactivation process to generate the clopidogrel active
metabolite. There are now evidence and guidelines for
implementing CYP2C19 genotyping, particularly for patients who undergo PCI for ACS. There remains some
controversy relating to the overall clinical relevance of
CYP2C19 genotyping for clopidogrel response for other
clinical conditions where clopidogrel is sometimes prescribed, such as in the setting of atrial fibrillation for
stroke prevention.

What is the current status of adopting pharmacogenetic testing into routine clinical practice when prescribing clopidogrel?
Jean Hulot: The use of pharmacogenetic testing in routine clinical practice remains limited mainly because the
genetic information is not available at the time of prescription. A couple of local initiatives have recently proposed to implement predetermined genetic profiles in the
electronic health records of selected patients. The platform thus gives doctors real-time guidance based on the
patient’s genetic profile.
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Clinical Chemistry 61:10 (2015)

Derek So: Currently, clinical guidelines do not endorse
adoption of routine pharmacogenetic testing for prescription of clopidogrel. However, the guidelines do suggest the consideration for use among special groups, such
as those with recurrent ACS despite ongoing treatment
with clopidogrel; accordingly, it has been given a class IIb
recommendation in current American College of Cardiology/AHA guidelines, with the intention of it to be reassessed after better clinical evidence becomes available.
Of note, the Spartan RX CYP2C19 test system and the
Nanosphere Verigene CYP2C19 Nucleic Acid Test are
FDA approved for in vitro testing and reimbursement via
Medicare (CPT code 81225). Therefore, its use on a
clinical basis is available for physicians in the United
States.
Should all patients on clopidogrel undergo pharmacogenetic testing, and if not who should be tested?
What polymorphisms should be genotyped? How
should the genotypes be determined and interpreted?
Jean Hulot: There is no evidence supporting a systematic
screening for patients requiring clopidogrel. Current data
rather indicate that CYP2C19 loss-of-function alleles
(mainly *2) are associated with higher cardiovascular outcomes in patients presenting with an ACS and requiring
PCI. CYP2C19 loss-of-function alleles have also been
associated with a higher risk to develop coronary stent
thrombosis.
Most of the studies have reported an increased cardiovascular risk in carriers of CYP2C19*2 receiving
clopidogrel. The influence of other loss-of-function alleles is more controversial, mainly because of their low
frequency. In addition, the risk is well demonstrated in
CYP2C19*2 homozygotes but remains a matter of debate
in heterozygotes. A large variability in clopidogrel response remains in CYP2C19*1/*2 and the appropriate
adjustment strategy in these patients remains unclear.
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Derek So: CYP2C19, an
isoenzyme in the cytochrome P450 system, has
been suggested to be integral in the biotransformation of clopidogrel. Lossof-function
CYP2C19
alleles, carried by up to
30% of individuals, have
been associated with increased adverse outcomes
in clopidogrel-treated patients with ACS undergoing PCI. The CYP2C19*2 allele
(rs4244285) constitutes 95% of all loss-of-function alleles for CYP2C19, while the CYP2C19*3 allele
(rs4986893) accounts for another 1% among those of
Western European descent. In Asians, the *3 allele is
found in up to 15% of the population. A metaanalysis of
9685 patients confirmed that carriers of CYP2C19 lossof-function alleles suffer from an increased incidence of
major adverse cardiac events (MACE) (hazard ratio,
1.55) and stent thrombosis (hazard ratio, 2.67) compared to noncarriers. Novel inhibitors of P2Y12mediated platelet inhibition, prasugrel and ticagrelor,
provide enhanced platelet inhibition compared to clopidogrel; however, these agents are associated with an increased risk of major bleeding. An ideal strategy would be
selective administration of more potent P2Y12 agents to
patients at high risk for ischemia. Meanwhile patients at
a low risk can remain on clopidogrel and can be spared
bleeding risks and costs associated with more potent
agents.

Richard Kim: Routine pharmacogenetic testing for
CYP2C19 is not recommended by the American Heart
Association (AHA) 2012 guidelines. Accordingly, there
has not been much progress in translation of CYP2C19
testing into routine clinical practice in the community.
However, it should be noted that a number academic
institutions have implemented hospital-wide reporting
of CYP2C19 genotypes in their electronic medical records to facilitate provider order entry decision support.
The recent approval of other P2Y12 antagonists such as
prasugrel and ticagrelor, which are not significantly affected by pharmacogenetic factors, has meant that
healthcare providers have the option of bypassing the
need or consideration for CYP2C19 genotyping by prescribing one of these agents rather than clopidogrel.

Q&A

Derek So: As mentioned above, routine pharmacogenetic testing of all patients with ACS or those undergoing
PCI cannot be supported by present evidence. However,
for at-risk patients, such as those with recurrent events, a
better understanding of the mechanisms underlying
treatment failure would be of benefit for a personalized
strategy.
If testing were to occur, the CYP2C19 loss-offunction alleles have the strongest evidence for association to ischemic complications, with the CYP2C19*2
and CYP2C19*3 variants comprising over 95% of lossof-function alleles. The ATP-binding cassette, subfamily B (MDR/TAP), member 1 (ABCB1) gene encodes an intestinal efflux pump and affects clopidogrel
gut uptake. Homozygous carriers of the ABCB1

c.3435C⬎T (rs1045642) variant have an increased propensity for ischemic outcomes after ACS when treated
with PCI and clopidogrel; accordingly, positioning it as a
possible variant for screening. Lastly, bleeding risk is also
an important consideration in the management of these
patients. The CYP2C19*17 is a gain-of-function allele
and has been associated with increased bleeding among
carriers treated with clopidogrel. A better understanding
of the interplay of these potential target variants would
enable future application of genetic data towards personalized antiplatelet treatment.
How does turnaround time factor in when determining a patient’s CYP2C19 genotype? What should the
target turnaround time be and is there a need for
rapid genotyping or point-of-care genotyping assays?
Jean Hulot: So far, the use of pharmacogenetic testing in
routine practice has been largely limited by the long turnaround time. Clopidogrel is likely prescribed in an emergency setting and any therapeutic adjustment should be
decided in a very limited time frame. The pharmacogenetic information should eventually be available at the
time of prescription. Point-of-care (POC) genotyping
assays might be part of the solution.
Richard Kim: CYP2C19 genotyping turnaround time is
likely of most relevance in the setting of ACS, when an
antiplatelet agent such as clopidogrel is likely to be prescribed. Indeed, in this population of patients, knowing
the genotype with a rapid turnaround time may be particularly helpful in terms of selecting clopidogrel vs other
agents. It is difficult to know what the target turnaround
time should be, but within 24 h would be desirable. Indeed, a number of POC genotyping technologies, including that of Spartan and Nanosphere Verigene systems, are available.
Derek So: As my colleagues indicated, the target patients
for this technology are those undergoing PCI or those
with ACS. Often management decisions for these patients must be made in an expedient manner since potential delays may incur risk for ischemic or bleeding complications. In patients undergoing PCI, the risk for stent
thrombosis is rare, but potentially devastating. This complication occurs most often within the first several days
after stent deployment; therefore, the potential use of
genetic testing would ideally be at the time of antiplatelet
initiation. Consequently, the most prudent argument for
genetic testing is a POC device that would enable very
quick turnaround of data, ideally within the first hour.
Even with this scenario, ACS patients may require initial
treatment with a more potent agent because delay to
angiography for proper diagnosis and management may
incur potential complications.
Clinical Chemistry 61:10 (2015) 1237
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Richard Kim: Currently, the strongest evidence exists
for CYP2C19 genotyping in the setting of ACS patients
who undergo PCI. This would be a group of patients who
merit preemptive genotyping. The recommendation for
interpretation of the CYP2C19 genotype for clopidogrel
is clearly outlined in the Clinical Pharmacogenetics
Implementation Consortium (CPIC) guideline. As
genotyping-associated costs continue to decline, and I
suspect in the future most patients will have CYP2C19
genotyping (or even NextGen sequencing) carried out as
a part of a much larger pharmacogenetic panel, the utility
of such test results will be in linking the results and recommendation at the time of initiation of antiplatelet
therapy. Although the cost of newer agents such as ticagrelor is higher than that of clopidogrel, it is possible
that such price gaps may narrow substantially in the coming years. However, for the foreseeable future, cost difference is likely to be a major consideration to CYP2C19
genotyping since a generic version of clopidogrel was approved by the FDA in 2012. Indeed, the cost of a 30-day
supply of clopidogrel appears to be near $12.00 at various
pharmacies in the United States while the list price for a
30-day supply of ticagrelor is nearly $285, although likely
much cheaper when using manufacturer coupon or assistance programs.
In terms of functional consequences, the common
CYP2C19*2 allele encodes for a complete loss of function
allele and is the most common and clinically relevant
genotype for those of Caucasian descent. It should be
noted that in other racial groups, such as Asiatics, in
addition to CYP2C19*2, the CYP2C19*3 allele, another
complete loss-of-function genetic variation is also observed with sufficient frequency. Therefore, interpretation of genotypes should include caveats that note the
current genotyping tests only rule in or out common
variants and being genotyped and being labeled as
CYP2C19*1/*1 does not guarantee the absence of other
more rare functional genetic variation(s) in the patient’s
DNA.

Q&A

What are the issues or challenges faced with pharmacogenetic testing, interpretation, and reporting to the
ordering physician?
Jean Hulot: Pharmacogenetic testing requires appropriate consent from the patient and specific authorizations
to be performed and interpreted. The pharmacogenetic
information will be used to adjust the patient therapies
with the hope of providing a more personalized treatment strategy that improves the efficacy while reducing
safety issues. On the other hand, any errors in genotyping
or interpreting the results might lead to inappropriate
treatment adjustment that could prove harmful. Presently, new P2Y12 antagonists are available and can be
used in place of clopidogrel. The efficacy of these drugs is
CYP2C19-independent but they are associated with a
higher risk of bleeding.
Richard Kim: Although there are a number of challenges
for the field of pharmacogenetics, for CYP2C19 genotyping in the setting of ACS and PCI, other than rapid
turnaround time and accuracy of the test results, there is
sufficient evidence to support the use of CYP2C19 genotyping information in selecting the most appropriate antiplatelet agent. Before the availability of newer agents
such as ticagrelor, substantial research effort had been
focused on identifying the best dose(s) of clopidogrel for
those who carry a variant allele. However, using
CYP2C19 genotype to guide antiplatelet drug selection
makes clinical recommendation simpler and easier for
requesting physicians to prescribe.
Derek So: Major obstacles to the use pharmacogenomics
in cardiology include lack of accessibility and the time
delay associated with conventional genotyping. Certainly, the advent of POC testing devices overcomes
some of these initial challenges and also provides physicians with data directly at the bedside. However, there
may be worries about the accuracy of the data compared
to conventional laboratory-based genotyping and the legal implications for miscalls. Conversely, conventional
1238

Clinical Chemistry 61:10 (2015)

laboratory-based genotyping may also be prone to clerical
errors in specimen labeling or reporting.
As stated, the lack of prospective trials demonstrating benefit from reduction in clinical endpoints with
genotyping is a barrier to the routine application of the
technology into antiplatelet selection. Also, genotyping
does not exclude all causes for variability in responsiveness to clopidogrel. Factors such as age, body mass index,
diabetes, and ACS have all been shown in the literature to
affect clopidogrel responsiveness. Therefore, genotyping
alone may not prevent all potential causes for ischemic
complications. In this context, combined approaches to
personalizing antiplatelet therapy may be required in future strategies.
Once the CYP2C19 genotype is determined and interpreted how should the clinician respond? Does
routine clinical pharmacogenetic testing make a
meaningful impact on clopidogrel therapy and patient outcomes?
Jean Hulot: Two different options have been proposed
so far: increasing the clopidogrel dosing regimen or
switching to another P2Y12 antagonist. Different studies
have shown that increasing the clopidogrel dosing regimen is not able to override clopidogrel resistance, thus
favoring the second option. However, one needs to remember that no prospective clinical trial has demonstrated the efficacy of a pharmacogenetic-guided prescription of a P2Y12 antagonist. On the other hand, most
of the pharmacological studies have shown that
CYP2C19*2 homozygous carriers are unable to activate
clopidogrel and the use of other P2Y12 antagonists in
these particular patients should be considered.
Richard Kim: The goal would be to provide specific
suggestions with regard to selecting clopidogrel or alternative drugs but leave the ultimate decision to the requesting physician. It is possible, for example, that even
when a variant allele is detected and reported, the clinician may choose to continue with clopidogrel if the clinician knows that the patient can only afford the cost of
generic clopidogrel. Indeed, since most patients with
ACS who undergo PCI are usually placed on low-dose
aspirin as well as a P2Y12 antagonist such as clopidogrel,
the impact of CYP2C19 genotype, for the majority of
variant carriers (CYP2C19 intermediate metabolizers),
may not be as large or clinically significant as those who
are true poor metabolizers.
Derek So: On the basis of accumulated evidence linking
CYP2C19 loss-of-function polymorphisms with MACE,
the FDA issued a boxed warning for clopidogrel in March
of 2010. Among patients in whom testing is felt to be
indicated, those who are identified as heterozygous or
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Currently available devices have capabilities to perform testing within the first hour. Subsequent generations of this technology may enable determination of
genetic carrier status within 30 min of test initiation.
While it may be argued that conventional laboratory testing may be used for patients undergoing elective PCI,
there are still logistical issues that may cause delays.
Therefore, if novel POC systems may provide sensitivity
and specificity equal to that of conventional genotyping
and at comparable costs, then it would be argued that
POC testing is the ideal modality for this group of
patients.

Q&A

Should pharmacogenetic testing be accompanied by
therapeutic drug monitoring or platelet function testing in patients taking clopidogrel?
Jean Hulot: There is no evidence supporting this approach, which will remain mainly experimental at that
stage.
Richard Kim: This topic has been controversial as well.
There is increasing evidence to support that on-treatment
platelet reactivity during clopidogrel therapy is greater for
those who possess CYP2C19 variant alleles. Indeed, there
are commercially available functional assays of platelet
reactivity, such as VerifyNow. However, it is not clear
that the cost associated with such functional assays in
addition to CYP2C19 genotyping will result in significantly better clinical decisions with regard to antiplatelet
drug selection, beyond CYP2C19 genotyping.
Derek So: Randomized studies based on platelet function testing have not been able to demonstrate a reduction in ischemic complications in lower-risk patients.
However, ongoing studies with novel designs are underway to elucidate this issue further. Genetics do not ac-

count for all causes of high on-treatment platelet reactivity. Therefore, it is possible that patients identified as
noncarriers of at-risk variants may actually have alternate
causes for underresponsiveness to clopidogrel. Ideally,
platelet function testing on these individuals may confer
additional information and further identify those at potential risk when treated with clopidogrel. Future strategies for individualizing antiplatelet therapy may undertake a combined approach to utilize several methods to
identify all at-risk individuals. At present though, the
evidence of this type of approach is lacking.
What is the future of pharmacogenetic testing for
clopidogrel therapy?
Jean Hulot: The pharmacogenetic influence on clopidogrel response was first reported in 2006 but there is still
an underuse of pharmacogenetic testing for clopidogrel
therapy. Technical issues explain part of this situation
and newly developed POC genotyping assays can address
these issues. CYP2C19 genetic variants are widely recognized as a main determinant of clopidogrel response but
they explain a limited proportion of the overall variability. The development of genome-wide techniques will
help identify other variants of importance. The combination of multiple variants might provide a more predictive and useful tool in the future.
Richard Kim: I think there is potential for broader pharmacogenetic testing for clopidogrel, driven in part by the
current lower cost of generic clopidogrel compared to
other agents in the same class, in the setting of increasingly lower genotyping costs. I suspect in the coming
years pharmacogenetic testing will be carried out as a
panel of tests, rather than having just one gene or genotype, and will be ready for use when drugs such as clopidogrel are prescribed, where the drug choice/dose decision support is built into the electronic medical record
system used by the prescribing physician. I suspect that
even when the cost of other antiplatelet drugs such as
ticagrelor becomes similar to generic clopidogrel, knowing CYP2C19 genotype may be helpful in assessing adverse reactions; drug-associated dyspnea is more frequent
among patients on ticagrelor compared to clopidogrel,
and bleeding risk appears to be greater for prasugrel.
Derek So: Currently, the 2 ongoing randomized studies
[Patient Outcome after primary PCI (POPular) and Tailored Antiplatelet Therapy following PCI (TAILORPCI)] of pharmacogentic testing are anxiously anticipated. TAILOR-PCI will enroll over 5000 patients and
will be the largest pharmacogenomic study to date. The
results from these studies may then guide the proper
adoption of the technology into routine clinical practice
and also direct future strategies of personalized antiplateClinical Chemistry 61:10 (2015) 1239
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homozygous CYP2C19 loss-of-function carriers are categorized as intermediate or poor metabolizers, respectively. The recommendation by the CPIC is to switch
clopidogrel for a more potent agent that is immune to
CYP2C19 influence, such as prasugrel or ticagrelor.
Testing may potentially benefit several groups.
From a patient’s perspective, those who are identified as
carriers of at-risk alleles would derive protection from
potentially receiving a drug, which may put them at risk
for ischemic complications. Conversely, for noncarriers,
there may be the potential benefit of not being exposed to
more potent agents, which may put them at risk for
bleeding complications. From a payer’s perspective, (patients, insurance companies, or national drug plans) there
may be substantial cost savings by being able to identify
those at risk and selectively treating them with the novel
P2Y12 inhibitors, while leaving low-risk patients on
clopidogrel, which is generic and several folds cheaper.
Also, the potential cost savings to healthcare plans by
avoiding treatment of bleeding complications should be
considered.
Opponents to routine testing would contend that
trials with definitive clinical outcomes would be warranted before substantiating the stated benefits above.
However, on an individual patient basis, it could be contended that it will be very difficult not to alter therapy if
a patient is identified as a carrier of an at-risk allele. Accordingly, physicians should really weigh potential implications of the test results before ordering genotyping on
patients on a routine basis.

Q&A
let therapy. A key benefit of this technology will be to try
to balance ischemia against bleeding outcomes and
achieve an ideal therapeutic window. Future studies like
POPular and RAPID MANAGE (Reassessment of AntiPlatelet Therapy Using InDividualized Strategies—
Modifying Acute CoroNary Syndrome Algorithms
Based on Genetic and Demographic Evaluation) will
likely use combined ischemic and bleeding outcomes or
net adverse clinical events to properly define benefits and
harm to patients.
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